CALA News and Press, Calithera Biosciences Inc. From 04/01/22

Image source: The Motley Fool. Calithera Biosciences (NASDAQ: CALA) Q4 2021 Earnings Call Mar 31, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences (CALA) Q4 2021 Earnings Call Transcript

Calithera Biosciences (CALA -10.9%) stock declined April 1 following its Q4 results post market Thursday. Q4 net loss widened to -$69.21M, compared to -$22.57M in Q4 2020. For 2021 net loss increased to -$115.09M, compared to -$90.14M in 2020. Research and development declined to $13.74M...

Calithera Biosciences, Inc. (CALA) Q4 2021 Earnings Conference Call March 31, 2022 05:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participants J...

Calithera Biosciences press release (NASDAQ:CALA): Q4 GAAP EPS of -$0.92 misses by $0.69. Cash, cash equivalents and investments totaled $59.5 million at December 31, 2021, which the Company expects, together with proceeds from its $10.0 million public offering, will be sufficient to meet its...

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2021. “In 2021, w...

Calithera Biosciences (NASDAQ:CALA) is scheduled to announce Q4 earnings results on Wednesday, March 30th, after market close. The consensus EPS Estimate is -$0.19 (+40.6% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 do...

Calithera Biosciences (NASDAQ:CALA) slumps 29.7% after hours after the firm has priced its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54/ share for expected gross proceeds of ~$10.0M. Each share of common...

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common...

Calithera Biosciences (NASDAQ:CALA) has slipped 21.38% after-hours on announcing an underwritten public offering of common stock and warrants to purchase common stock. The biopharmaceutical company plans to sell shares of its common stock, warrants to purchase shares of its common s...

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, warrants to purchase shares of its common...